Cibc World Markets Corp Increases Stock Position in Pfizer Inc. (NYSE:PFE)

Cibc World Markets Corp lifted its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 17.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 902,242 shares of the biopharmaceutical company's stock after buying an additional 133,084 shares during the quarter. Cibc World Markets Corp's holdings in Pfizer were worth $23,936,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Retirement Wealth Solutions LLC acquired a new position in shares of Pfizer during the 4th quarter worth about $26,000. Rialto Wealth Management LLC acquired a new stake in Pfizer during the 4th quarter worth $26,000. Kohmann Bosshard Financial Services LLC purchased a new stake in Pfizer in the fourth quarter valued at $28,000. Noble Wealth Management PBC acquired a new position in Pfizer in the fourth quarter valued at $31,000. Finally, Teachers Insurance & Annuity Association of America acquired a new stake in shares of Pfizer during the third quarter worth about $35,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Bank of America restated a "neutral" rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a report on Monday, March 10th. UBS Group decreased their price objective on Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research report on Wednesday, January 8th. Guggenheim reissued a "buy" rating on shares of Pfizer in a report on Tuesday. Finally, StockNews.com lowered shares of Pfizer from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Pfizer currently has an average rating of "Moderate Buy" and an average price target of $31.92.

Remove Ads

Insiders Place Their Bets

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares of the company's stock, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.06% of the company's stock.

Pfizer Price Performance

Shares of NYSE PFE traded up $0.26 on Tuesday, hitting $26.31. The company's stock had a trading volume of 32,949,032 shares, compared to its average volume of 35,799,303. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a 50 day moving average of $26.22 and a 200-day moving average of $27.10. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The company has a market capitalization of $149.09 billion, a price-to-earnings ratio of 18.66, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the previous year, the business posted $0.10 earnings per share. The company's revenue was up 24.7% on a year-over-year basis. As a group, research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.